SEER: Seer EV/EBITDA Multiple

Seer, Inc. (SEER) develops systems for detailed proteome analysis, locking customers into the regular purchase of proprietary reagents. Current revenues are based on the sale of advanced platforms for biolabs, while the daily price chart reflects a value for the 0.00 metric. The business relies on unique Proteograph nanotechnologies, which enable the rapid study of thousands of proteins to identify pathologies at the earliest stages.

Seer Bio - SEER Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/11/2026)

Summary analytical data breakdowns for seer.bio (SEER)

- stock price and consensus target price:

Stock Quotes Seer Inc.|SEER - Analyst Forecast Prices

- market capitalization information:

Market Capitalization Seer Bio|SEER - Company Buyout Price

- issuer book value statistics:

Book Value per Share Seer|SEER - Company Net Assets|Market Cap to Net Assets Ratio seer.bio|SEER - Aggregate Asset Value

- company liabilities and liquidity data:

- financial results and valuation multiples details:

SEER - Net Income|Projected Future Earnings Seer, Inc.|SEER - P/E Multiple|Future Price to Earnings Seer, Inc.|SEER - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Seer Bio|SEER - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Seer|SEER - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months seer.bio|SEER - Net earnings per share change in current year|Expected earnings per share growth for next year Seer, Inc.

Initial company analysis:Seer Inc. SEER

For Seer, Inc. (SEER), with its narrow specialization in a single proteomic platform, this indicator serves as a tool for monitoring debt load relative to operational efficiency. The metric compares the enterprise value, including net debt, against earnings before interest, taxes, depreciation, and amortization. By analyzing the historical EV/EBITDA chart for Seer, Inc. (SEER), an investor can determine the degree of leverage during the commercialization of the technology. A declining ratio signals either an undervalued asset or a critical increase in risk.

Competitor analysis for Seer, Inc.

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Hyperfine Medical (HYPR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR Corporation FONR|Daxor Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)